Reduce Sedentary Time in Acute Lymphoblastic Leukemia
NCT06182163 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2026-02-02
Summary
The goal of this feasibility trial is to test if a mobile health intervention, including a wearable fitness tracker with inactivity-triggered reminders to move, individualized coaching sessions, and an app-based peer support group, can decrease sedentary time (time spent sitting/lying down and inactive) in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) receiving maintenance chemotherapy. The main questions it aims to answer are:
* Is the intervention a feasible and acceptable way to decrease sedentary time among adolescents and young adults (AYAs) with ALL?
* Does the intervention show evidence that it may decrease sedentary time?
* Does the intervention show evidence that it may increase quality of life, reduce inflammation, and improve glucose and lipid metabolism?
Participants will use their fitness tracker with reminders to move as well as support from other intervention participants and coaching with study staff to gradually decrease their sedentary time over 10 weeks. Researchers will compare participant pre- and post-intervention study measures to see if the program may be helpful to decrease sedentary time in adolescents and young adults (AYAs) with ALL. All participants will wear an activity tracker on the thigh for 7 days at the beginning and end of the study as well as complete quality of life questionnaires. Study labs will be collected three times (baseline, 8 weeks, and 12 weeks) over the course of the 12-week study. All in-person study visits and labs will occur in conjunction with Oncology clinic visits for maintenance chemotherapy.
Conditions
- Acute Lymphoblastic Leukemia (ALL)
Interventions
- BEHAVIORAL
-
Sedentary time intervention
Tests the effect of a multi-component mobile health (mHealth) intervention on reducing sedentary behavior among adolescents and young adults (AYAs) with ALL during maintenance therapy. The intervention includes an app-based peer support group for study participants via WhatsApp, individualized coaching sessions with study staff, and prompts to move delivered via a Fitbit wearable fitness tracker.
Sponsors & Collaborators
-
St. Baldrick's Foundation
collaborator OTHER -
Rally Foundation for Childhood Cancer Research
collaborator OTHER -
Children's Hospital Los Angeles
lead OTHER
Principal Investigators
-
Brittany J Ivory (Van Remortel), MD, MPH · Children's Hospital Los Angeles
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 12 Years
- Max Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-01
- Primary Completion
- 2025-12-10
- Completion
- 2025-12-10
Countries
- United States
Study Locations
More Related Trials
-
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
NCT01190930 ·Status: COMPLETED ·Phase: PHASE3
-
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00720109 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
NCT06446661 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home
NCT06639958 ·Status: SUSPENDED ·Phase: NA
-
Study of Long-Term Outcomes of Patients With Acute Lymphoblastic Leukemia Who Were Enrolled as Children on Clinical Trials EORTC-58741, EORTC-58831, EORTC-58832, or EORTC-58881 Between 1971 and 1998
NCT01298388 ·Status: UNKNOWN
-
Home-exercise Program for Children and Adolescent Survivors of Acute Lymphoblastic Leukemia
NCT03005392 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
NCT02883049 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
NCT06697600 ·Status: RECRUITING ·Phase: NA
-
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
NCT00075725 ·Status: COMPLETED ·Phase: PHASE3
-
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
NCT00061945 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
NCT06289673 ·Status: RECRUITING ·Phase: PHASE4
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00103285 ·Status: COMPLETED ·Phase: PHASE3
-
Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission
NCT02126553 ·Status: COMPLETED ·Phase: PHASE2
-
Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT00003790 ·Status: COMPLETED
-
Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL
NCT07278882 ·Status: RECRUITING ·Phase: NA
-
Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003
NCT00222612 ·Status: UNKNOWN ·Phase: PHASE4
-
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
NCT00002989 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluation of Long-term Health Status and Quality of Life in Adult Survivors With Philadelphia-negative Acute Lymphoblastic Leukemia/Lymphoma Treated With an Intensive Pediatric or Pediatric-inspired Protocol
NCT04677231 ·Status: UNKNOWN
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00558519 ·Status: COMPLETED ·Phase: PHASE2
-
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
NCT00458523 ·Status: COMPLETED ·Phase: PHASE2
-
Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia
NCT01245231 ·Status: COMPLETED
-
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
NCT02881086 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00016302 ·Status: COMPLETED ·Phase: NA
-
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
NCT04301076 ·Status: SUSPENDED ·Phase: PHASE1
-
Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia
NCT00342316 ·Status: COMPLETED ·Phase: NA